Chemomab Therapeutics Ltd. American Depositary Share
CMMBStock
$1.52−66.96%52W
Market Cap$10.94M
P/E—
Div yield—
Beta0.68
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-29.46%
Price vs S&P 500 (4W)-7.91%
VGM Score25.52
Market Capitalization$10.94M
Earnings Surprise History
Q1 26-0.24est. -0.16
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMMBChemomab Therapeutics Ltd. American Depositary Share | — | — | D | $1.52 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Chemomab Therapeutics is a clinical-stage biotech company developing CM-101, a monoclonal antibody targeting CCL24 for fibrosis-related diseases with significant unmet medical needs. The company's lead candidate employs a novel mechanism to address liver, skin, and lung fibrosis, with three Phase 2 trials currently underway for rare fibrotic conditions.